CBD Oral solution, is known as Epidyolex and is the approved name in the EU

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
156	レット症候群	2

156. レット症候群

臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001605-24-GB (EUCTR)	15/01/2020	23/10/2019	An open label extension study for long-term safety of GWP42003-P in patients with Rett Syndrome	An open-label extension trial to investigate thelong-term safety of cannabidiol oralsolution (GWP420 ...	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 1007770 ...	Trade Name: CBD Oral solution, is known as Epidyolex and is the approved name in the EU Product Name: ...	GW Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 3	United States;France;Canada;Spain;Australia;Italy;United Kingdom
2	EUCTR2018-003370-27-GB (EUCTR)	09/04/2019	24/12/2018	A randomized, double-blind, placebo-controlled trial to investigate theefficacy andsafety of cannabi ...	A randomized, double-blind, placebo-controlled trial to investigate theefficacy andsafety of cannabi ...	Rett syndrome (RTT) [typical or atypical] MedDRA version: 20.0;Level: PT;Classification code 1007770 ...	Trade Name: CBD- Oral Solution, is known as Epidyolex, and is the approved name Product Name: Cannabi ...	GW Research Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 2;Phase 3	United States;France;Canada;Spain;Australia;Italy;United Kingdom

First Previous1Next Last